Resistance, Rebound, and Recurrence Regrowth Patterns in Pediatric Low-Grade Glioma Treated by MAPK Inhibition: A Modified Delphi Approach to Build International Consensus

Medicine, Pediatrics, Neurology, Neurosurgery, Oncology,
Pediatric   Low-Grade Glioma   MAPK Inhibition   Resistance   Recurrence   Rebound   Delphi Method  

International Consensus on Resistance, Rebound, and Recurrence in Pediatric Low-Grade Glioma with MAPK Inhibition Therapy: Established Using a Modified Delphi Method Academic Background Pediatric low-grade glioma (PLGG) is the most common type of tumor in the central nervous system of children. Although these tumors have a relatively high overall s...

Raman-Based Machine Learning Platform Reveals Unique Metabolic Differences Between IDHmut and IDHwt Glioma

Information Science, Artificial Intelligence, Medicine, Medical Laboratory Science, Neurology, Medical Imaging, Oncology, Life Sciences, Cell Biology, Biochemistry,
Raman spectroscopy   glioma   machine learning   FFPE tissue   lipid metabolism  

Study on Metabolic Differences between IDH Mutant and Wild-type Glioma Cells Using Raman Spectroscopy and Machine Learning Platform Background Introduction In the diagnosis and treatment of gliomas, formalin-fixed, paraffin-embedded (FFPE) tissue sections are commonly used. However, due to background noise interference from the embedding medium, th...

Disturbance in Cerebral Blood Microcirculation and Hypoxic-Ischemic Microenvironment are Associated with the Development of Brain Metastasis

Medicine, Neurology, Neurosurgery, Oncology, Life Sciences, Immunology,
cerebral blood microcirculation   hypoxic-ischemic microenvironment   brain metastasis   angiogenesis   ANG-2   VEGF   anti-angiogenic therapy  

Microcirculatory Disorders of Cerebral Blood Flow and the Hypoxic-Ischemic Microenvironment Related to Brain Metastasis Development Background and Research Motivation Brain metastasis (BM) is an increasing challenge in oncology due to its severe impact on neurological function, limited treatment options, and resulting poor prognosis. BM develops th...

Risk Factors for Domain-Specific Neurocognitive Outcome in Pediatric Survivors of a Brain Tumor in the Posterior Fossa – Results of the HIT 2000 Trial

Medicine, Pediatrics, Neurology, Neurosurgery, Clinical Psychology, Oncology,
Neurocognitive outcome   Pediatric brain tumor   Posterior fossa   HIT 2000 trial   Risk factors analysis  

Analysis of Risk Factors Related to Specific Domain Neurocognitive Outcomes in Pediatric Survivors of Posterior Fossa Brain Tumors – HIT 2000 Trial Results Research Background Brain tumors are the most common solid tumors in childhood, particularly central nervous system (CNS) tumors. Studies have shown that patients who receive craniospinal irradi...

Representation of Genomic Intratumor Heterogeneity in Multi-Region Non-Small Cell Lung Cancer Patient-Derived Xenograft Models

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
non-small cell lung cancer   xenograft models   tumor heterogeneity   genomic evolution   multi-region sampling  

Manifestations of Genomic-Level Intratumoral Tumor Heterogeneity in Multi-Region Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer Academic Background and Research Motivation Patient-Derived Xenograft (PDX) models are widely used in cancer research. PDX models are established by transplanting human tumors into immunodeficient mice. The...

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML

Medicine, Basic Medical Sciences, Hematology, Oncology, Life Sciences, Biochemistry,
orthogonal proteogenomic   acute myeloid leukemia   EVI1   PA2G4   druggable target   histone deacetylase inhibitors  

Orthogonal Proteogenomic Analysis Identifies Druggable PA2G4-MYC Axis in 3q26 AML Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive malignancy. In particular, the 3q26 chromosomal abnormality subtype of AML has a complex pathogenic mechanism and lacks effective targeted therapies. To address this challenge, Matteo Marchesini and...